Stayble Therapeutics
0.595
SEK
+5.31 %
STABL
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
+5.31%
-6.3%
-23.72%
+142.86%
+96.37%
+80.3%
-91.22%
-
-92.05%
staybletherapeutics.com/sv/investerare/oversikt
Stayble Therapeutics operates in the pharmaceutical industry. The company specializes in research and development of injection treatments for pain caused by herniated discs. The drug candidates are developed and based on a proprietary technological platform. Most operations are found in the Nordic market and the company has its headquarters in Gothenburg.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
STABL
Daily low / high price
0.565 / 0.605
SEK
Market cap
26.01M SEK
Turnover
40.04K SEK
Volume
69K
Financial calendar
Interim report
2024-11-29
Annual report
2025-02-25
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Stiftelsen Chalmers Tekniska Högskola | 10.6 % | 10.6 % |
| Avanza Pension | 6.5 % | 6.5 % |
| ALMI Invest Västsverige AB | 6.1 % | 6.1 % |
| Nordnet Pensionsförsäkringar AB | 6.0 % | 6.0 % |
| Handelsbanken Liv | 3.0 % | 3.0 % |
| Robert Joki | 2.8 % | 2.8 % |
| Magnus Kumbrant | 2.0 % | 2.0 % |
| Futur Pension | 1.9 % | 1.9 % |
| Alirami Baftijari | 1.7 % | 1.7 % |
| Ålandsbanken ABP | 1.6 % | 1.6 % |
ShowingAll content types
Stayble Therapeutics' STA363 receives positive phase 1b results
Stayble Therapeutics: Europeiska patentmyndigheten meddelar sin avsikt att bevilja Staybles patent för behandling av diskbråck
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools